Corbus Pharmaceuticals Holdings, Inc. SEC Filings

BlackRock, Inc. reports beneficial ownership of common stock of Corbus Pharmaceuticals Holdings Inc. BlackRock and certain of its business units collectively beneficially own 1,093,434 shares of Corbus common stock, representing 5.9% of the outstanding class as of the reported date.

BlackRock has sole voting power over 1,081,182 shares and sole dispositive power over 1,093,434 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds from these shares, but no single client holds more than five percent of Corbus’s outstanding common stock.

The issuer with ticker CRBP filed a notice that affiliate Dominic Smethurst may sell 23,025 shares of common stock through broker Stifel Nicolaus & Company Inc. on or about July 27, 2026 on the Nasdaq market.

The filing references common stock underlying restricted stock units granted on four dates in 2025–2026 and notes that Smethurst previously sold 3,334 shares of common stock for 31,001.00 on July 2, 2026.

Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer under a two-year employment agreement effective August 3, 2026. His package includes a $545,000 annual base salary, a target bonus of up to 40% of base pay, and equity awards with an aggregate grant date fair value of $2.1 million, split roughly 75% stock options and 25% restricted stock units with multi‑year vesting.

The agreement provides severance of up to 18 months of base salary, COBRA reimbursement and accelerated equity vesting if he is terminated without cause or resigns for good reason during a defined change in control period, subject to a release and non‑compete. Corbus also highlighted upcoming milestones: initiation of the TEMPO‑1 registrational trial of CRB‑701 in second‑line oropharyngeal squamous cell carcinoma in summer 2026, a 250‑patient randomized study targeting overall response rate for potential accelerated approval, a planned similar trial in second‑line cervical cancer, and topline data from the CANYON‑1 Phase 1b obesity study of CRB‑913 in 240 patients expected in late summer 2026, with additional CRB‑701 data in first‑line OPSCC anticipated in early 2027.

Corbus Pharmaceuticals director Winston Kung sold 2,026 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $7.9137 per share, with individual sale prices ranging from $7.71 to $7.97.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. After this transaction, Kung holds 12,140 shares directly, which includes 3,800 unvested restricted stock units subject to the grant’s vesting schedule.

Corbus Pharmaceuticals Holdings director Anne Altmeyer sold 2,412 shares of common stock in an open-market transaction at a weighted average price of $7.9137 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026.

These shares were sold in multiple trades at prices ranging from $7.71 to $7.97. After the sale, Altmeyer directly holds 7,579 shares of common stock, which includes 3,800 unvested restricted stock units that remain subject to the grant’s vesting schedule.

Corbus Pharmaceuticals Holdings, Inc. director John Kenneth Jenkins reported an open-market sale of 4,800 shares of common stock on June 10, 2026 at a weighted average price of $7.9137 per share, executed under a Rule 10b5-1 trading plan. Following this sale, he directly holds 3,833 shares of common stock and 3,800 unvested RSUs subject to the grant’s vesting schedule.

Corbus Pharmaceuticals Chief Business Officer Nishant C. Saxena bought 13,500 shares of common stock in open-market transactions. He purchased 9,000 shares at $7.58 per share on June 3 and 4,500 shares at a weighted average price of $7.33 per share on June 2, in multiple trades between $7.33 and $7.34. Following these purchases, he directly holds 75,300 common shares, including 58,300 unvested RSUs that remain subject to the grant’s vesting schedule.

Corbus Pharmaceuticals reported updated Phase 1/2 data for its Nectin‑4 antibody‑drug conjugate CRB‑701 in second‑line oropharyngeal head and neck cancer (OPSCC) and cervical cancer. At the 3.6 mg/kg dose, confirmed objective response rates reached 42.9% in OPSCC and 34.4% in cervical cancer, with median durations of response of 6.3 and 8.0 months and progression‑free survival of 5.6 and 4.3 months, respectively.

Across 317 treated patients, CRB‑701 was generally well tolerated, with Grade 3 and 4 adverse events in 19.2% and 0.9%, no Grade 5 events, and treatment discontinuations of 2.8%. Ocular side effects were common but rarely led to discontinuation, and peripheral neuropathy was infrequent and mild.

Corbus plans to start a registrational TEMPO‑1 trial in 2L OPSCC in summer 2026 and has FDA alignment on randomized designs in both 2L OPSCC and 2L cervical cancer, supported by Fast Track designations. The company also highlighted early obesity data for oral CB1 inverse agonist CRB‑913, showing 2.9% placebo‑adjusted weight loss at day 14 in a 150 mg cohort.

Corbus Pharmaceuticals Holdings, Inc. reported that Chief Business Officer Nishant C. Saxena received new equity awards. On May 21, 2026, he was granted 58,300 restricted stock units (RSUs) that will settle in common shares, bringing his direct common stock holdings to 61,800 shares.

The RSUs vest 25% on each of the first four anniversaries beginning May 21, 2027, with partial acceleration possible if he is terminated without cause after the first vesting date. He was also granted options for 192,300 shares of common stock at an exercise price of $11.51 per share, expiring in 2036, which vest 25% on May 21, 2027 and the remaining 75% in equal monthly installments over 36 months starting June 21, 2027.